William K. Oh, MD

William K. Oh, MD

Icahn School of Medicine at Mount Sinai

New York, New York

William K. Oh, MD, an expert in the management of genitourinary malignancies, including prostate, renal, bladder, and testicular cancers, is Clinical Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief Medical Officer of The Prostate Cancer Foundation. Dr. Oh’s research interests include novel biomarkers and therapeutics in advanced prostate cancer. In addition to serving as the Principal Investigator of multiple clinical trials in prostate cancer, he has developed large clinical databases and specimen repositories for genitourinary cancers at Harvard Medical School and the Dana-Farber Cancer Institute and at Mount Sinai, which have enrolled more than 10,000 patients with prostate, renal, and bladder cancer. Dr. Oh has authored more than 300 articles, reviews, and book chapters on topics relating to prostate, renal, bladder, and testicular cancers. He has edited three books on prostate cancer. He has served in key invited roles for the American Society of Clinical Oncology, the American Cancer Society, and the American Urological Association, including the Guidelines Committee for Advanced Prostate Cancer. In addition to reviewing for top journals such as The New England Journal of Medicine, Journal of Clinical Oncology, and Cancer, Dr. Oh co-edits “Testicular Cancer” for Up to Date and is Associate Editor of CA: A Cancer Journal for Clinicians. He is a member of the prestigious American Society for Clinical Investigation and has been repeatedly selected as a Top Doctor in New York magazine, Castle Connolly, Best Doctors, and Super Doctors over the past decade. Dr. Oh received his MD from New York University School of Medicine. He completed his internship and residency in internal medicine at Brigham and Women’s Hospital in Boston. He then completed a fellowship in medical oncology at the Dana-Farber Cancer Institute in 1997. Prior to joining Mount Sinai in 2009, Dr. Oh served as Clinical Director of the Lank Center for Genitourinary Oncology and directed the Gelb Center for Translational Research at the Dana-Farber Cancer Institute and Harvard Medical School in Boston. He was also the founding Chair of the Data and Safety Monitoring Committee for Phase I/II Trials at the Dana-Farber/Harvard Cancer Center.


Talks by William K. Oh, MD

New Standards of Care for Advanced Prostate Cancer

In this 20-minute presentation, William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, addresses new standards of care in 2021 for advanced prostate cancer and focuses on non-metastatic castration-resistant prostate cancer (nmCRPC), concluding that apalutamide, enzalutamide, and darolutamide improve MFS in men with nmCRPC by ~2 years; SPARTAN, PROSPER, and ARAMIS established favorable benefit-risk for patients with nmCRPC and PSADT<10 months; and these studies provide the best evidence supporting early treatment. He also focuses on metastatic, hormone-sensitive prostate cancer (mHSPC) and concludes that upfront treatment with either abiraterone + prednisone, apalutamide, enzalutamide, or docetaxel is the standard of care and he asserts that new evidence from PEACE-1 and ARASENS supports triple therapy with a novel hormonal therapy +ADT+docetaxel for chemotherapy patients.

Read More

Join the GRU Community

- Why Join? -